Cargando…

Brentuximab-induced hand-foot syndrome in a patient with cutaneous T-cell lymphoma

Detalles Bibliográficos
Autores principales:	Shaposhnik, Guy, Jang, Sekwon, DeSimone, Jennifer A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856947/ https://www.ncbi.nlm.nih.gov/pubmed/35242962 http://dx.doi.org/10.1016/j.jdcr.2021.12.032

Ejemplares similares

Oral mycosis fungoides with CD30(+) large cell transformation successfully treated with brentuximab vedotin
por: Goggins, Clare A., et al.
Publicado: (2019)

Primary Cutaneous Anaplastic Large Cell Lymphoma of the Oral Cavity Successfully Treated with Brentuximab Vedotin
por: Meconi, Federico, et al.
Publicado: (2019)

Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma
por: Irimia, Ruxandra, et al.
Publicado: (2023)

Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
por: Wu, Hung-Bo, et al.
Publicado: (2013)

Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy
por: Onaka, Takashi, et al.
Publicado: (2018)

Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin
por: Şahin, Mustafa, et al.
Publicado: (2021)

Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma
por: Alderuccio, Juan Pablo, et al.
Publicado: (2018)

Brentuximab vedotin induced uveitis
por: Therssen, Stijn, et al.
Publicado: (2022)

Combined Modality Treatment With Brentuximab Vedotin and Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: A Case Report
por: Floyd, Erin G., et al.
Publicado: (2019)

Brentuximab Vedotin Therapy for Cutaneous Lesions in T-Prolymphocytic Leukemia: A Case Report
por: Senchak, Jordan, et al.
Publicado: (2016)

Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin
por: Uchimura, Ayana, et al.
Publicado: (2022)

Aggressive Primary Cutaneous Anaplastic T-Cell Lymphoma Successfully Treated with Autologous Stem Cell Transplant and Brentuximab Vedotin Consolidation: Case Report and Review of the Literature
por: Guarnera, Luca, et al.
Publicado: (2022)

Brentuximab vedotin as monotherapy for unresectable breast implant‐associated anaplastic large cell lymphoma
por: Stack, Anthony, et al.
Publicado: (2019)

Severe Acute Pulmonary Toxicity Associated with Brentuximab in a Patient with Refractory Hodgkin's Lymphoma
por: Sabet, Yasmin, et al.
Publicado: (2016)

Case Report: Cryptococcal meningitis in Hodgkin’s Lymphoma patient receiving brentuximab-vedotin therapy
por: Cunha Pereira, Tatiana, et al.
Publicado: (2020)

Severe Insulin Resistance in a Patient Treated With Nivolumab and Brentuximab-Vedotin for Hodgkin Lymphoma
por: Tama, Elif, et al.
Publicado: (2023)

Brentuximab Vedotin in CD30+ Lymphomas
por: Perini, Guilherme Fleury, et al.
Publicado: (2013)

Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with RUNX3 overexpression
por: Yamashita, Yusuke, et al.
Publicado: (2020)

Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
por: Tsang, Vivian
Publicado: (2012)

Brentuximab-Induced Colitis in a Non-Stem-Cell Transplant Patient
por: Ali, Sareena, et al.
Publicado: (2023)

Brentuximab vedotin use in pediatric anaplastic large cell lymphoma
por: Agrusa, Jennifer E., et al.
Publicado: (2023)

Docetaxel-induced hand foot syndrome: “No dose is a safe dose”
por: Jain, Ankit, et al.
Publicado: (2012)

Successful Treatment of a Patient with Brentuximab Vedotin-Refractory ALK-Negative Anaplastic Large Cell Lymphoma with Romidepsin
por: Jo, Tatsuro, et al.
Publicado: (2020)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)

A Rare Case of Grey Zone Lymphoma Successfully Treated with Brentuximab Vedotin and R-CHP Chemotherapy
por: Mallipudi, Rajiv M., et al.
Publicado: (2019)

Prolonged Remission by Pembrolizumab and Brentuximab-Vedotin Combination Therapy in Heavily-Pretreated Relapsed/Refractory Hodgkin’s Lymphoma
por: Yu, Tsung-Ying, et al.
Publicado: (2020)

Successful salvage therapy for refractory primary cutaneous gamma-delta T-cell lymphoma with a combination of brentuximab vedotin and gemcitabine
por: Voruz, Sophie, et al.
Publicado: (2021)

Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma
por: Heidegger, Simon, et al.
Publicado: (2014)

Cost-Effectiveness of Brentuximab Vedotin Versus Physician’s Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada
por: Elsea, David, et al.
Publicado: (2023)

Docetaxel-induced Hand and Foot Syndrome in a Patient with Metastatic Breast Carcinoma
por: Gurumurthi, Ravichandran, et al.
Publicado: (2013)

Treatment with rituximab and brentuximab vedotin in a patient of common variable immune deficiency-associated classic Hodgkin lymphoma
por: Rael, Efren, et al.
Publicado: (2016)

Near Complete Response in a Patient with Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin Concurrent with Radiation Therapy
por: Montana, Wilbur, et al.
Publicado: (2017)

Successful treatment of primary bone marrow Hodgkin lymphoma with brentuximab vedotin: a case report and review of the literature
por: Nagaharu, Keiki, et al.
Publicado: (2018)

A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin
por: Cao, Zhi-Gang, et al.
Publicado: (2013)

Onychomadesis Developed Only on the Nails Having Cutaneous Lesions of Severe Hand-Foot-Mouth Disease
por: Shikuma, Emi, et al.
Publicado: (2011)

Hand-foot-genital syndrome - analysis of two cases
por: Piazza, Mauri J., et al.
Publicado: (2018)

Cytomegalovirus Infection With Retinitis After Brentuximab Vedotin Treatment for CD30(+) Lymphoma
por: Tudesq, Jean-Jacques, et al.
Publicado: (2017)

Desensitization of Brentuximab Vedotin in a Patient with Hodgkin Lymphoma
por: Khalid, Sidra, et al.
Publicado: (2018)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019)

Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data
por: Horwitz, Steven M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ts3vm2d2bkon9pl8kt8iifa0gd